HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Solar Cosmetic Labs

This article was originally published in The Rose Sheet

Executive Summary

Solar Cosmetic Labs: Miami, FL-based sunscreen manufacturer receives FDA warning letter in December citing deviations from Current Good Manufacturing Practice (CGMP) regulations for drugs. The violations outlined in the Dec. 6 FDA letter include: failure to assure that sunscreens have met standards of strength, quality and purity; failure to "validate the analytical method for percent active ingredients"; failure to perform or maintain adequate stability testing; and failure to establish that the SPF rating is kept through a three-year shelf life. The letter also cites the company's lack of written procedures for the cleaning and maintenance of equipment, the handling of consumer complaints and the testing of raw materials and lab controls. In a Jan. 31 letter to FDA, the Miami-based company confirmed that "all actions have been taken to correct the violations"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS002513

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel